Publicly traded North American specialty pharmaceutical company in search of additional assets to launch in Canada
Case Details
Client profile: North American, publicly-traded specialty pharma, focused on CNS and cardiovascular disease
Client Need: In-licensing to expand portfolio
Result: $65M in-licensing deal, market cap doubled
The Challenge
- Our client was looking for additional assets to launch within the Canadian Market.
- Shadow Lake Group identified a specialty cardiovascular product commercialized in the U.S. by a publicly traded biotechnology company as a compelling opportunity for our client.
- However the product owner was not interested in partnering the Canadian Market as it was not a strategic priority.
What Did Shadow Lake Do?
SLG, over the course of several meetings directly with the product owner, was able to convey the value and viability of the Canadian market. More importantly, heavy emphasis was placed on the expertise and advantage of partnering the product with our client for this market.
The Results
- Our client in-licensed the product for Canada for a multi-million dollar deal value.
- Our client’s market capitalization doubled.